Lonnie Moulder, Zenas BioPharma CEO
August 22, 2024 03:27 PM EDTUpdated August 23, 08:12 AM
Financing
Startups

Au­toim­mune biotech Zenas files for IPO amid sum­mer lull for pub­lic de­buts

Kyle LaHucik

Senior Reporter

Zenas Bio­Phar­ma filed for an ini­tial pub­lic of­fer­ing on Thurs­day, mark­ing a rare move for biotech star­tups this sum­mer.

The late …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Mod­er­na plans $1.1B in R&D and pro­gram cuts, de­lays break-even point to 2028

Sofinno­va’s Jim Healy on ‘more ra­tio­nal mar­ket’ as four biotech star­tups near their IPOs

Charles Riv­er to lay off 3% of staffers as it stream­lines spend­ing

Ful­crum's Phase 3 for old GSK drug fails, stock sinks

Sanofi buys in­to ra­dio­phar­ma­ceu­ti­cal field with $110M up­front, go­ing af­ter space held by No­var­tis

A new start­up wants to fight can­cer with 'off-the-shelf' gene ther­a­py, se­cur­ing $26M seed round

A service from the Financial Times